Importantly, we demonstrate that Jak2/IDH-mutant MPN is highly sensitive to IDH-mutant inhibition and that combined Jak2/IDH-mutant–directed targeted therapy has potent antileukemic effects. This evidence concerns the gene IDH1 and myeloproliferative disorder.